Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 3, Mars 2004
Page(s) 317 - 324
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004203317
Publié en ligne 15 mars 2004
  1. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution : second look. J Mol Biol 1996; 260 : 623–37. [Google Scholar]
  2. Courtois S, Verhaegh G, North S, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 44 : 6722–8. [Google Scholar]
  3. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90 : 809–19. [Google Scholar]
  4. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating death-inducing and dominant negative activities. Mol Cell 1998; 2 : 305–16. [Google Scholar]
  5. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants : p63, p73 and the rise of p53. Trends Genet 2002; 18 : 90–5. [Google Scholar]
  6. Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol Cell Biol 2002; 22 : 2575–85. [Google Scholar]
  7. Kartasheva N, Contente A, Lenz-Stöppler C, et al. p53 induces the expression p73 delta N, establishing an autoregulatory feedback loop. Oncogene 2002; 21 : 4715–22. [Google Scholar]
  8. Vossio S, Palescandolo E, Pediconi N, et al. DeltaN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21 : 3796–803. [Google Scholar]
  9. Larsen CJ. The ARF-p53 pathway : a line of defense against oncogenic signals. Bull Cancer 1998; 85 : 9–19. [Google Scholar]
  10. Zeng X, Chen L, Jost CA, et al. Mdm2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19 : 3257–66. [Google Scholar]
  11. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1 interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275 : 36316–23. [Google Scholar]
  12. Calabro V, Gelsomina M, Parisi T, et al. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277 : 2674–81. [Google Scholar]
  13. Stiewe T, Pützer BM. Role of p73 in malignancy tumor suppressor or oncogene ? Cell Death Differ 2002; 9 : 237–45. [Google Scholar]
  14. Jost CA, Marin MC, Kaelin WG. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389 : 191–4. [Google Scholar]
  15. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416 : 560–4. [Google Scholar]
  16. Sah VP, Attardi LD, Mulligan GJ, et al. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995; 10 : 175–80. [Google Scholar]
  17. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356 : 215–21. [Google Scholar]
  18. Miller FD, Pozniak CD, Walsh GS. Neuronal life and death : an essential role for the p53 family. Cell Death Differ 2000; 7 : 800–88. [Google Scholar]
  19. Lowe S, Ryley H, Jacks T, Houssman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74 : 957–67. [Google Scholar]
  20. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398 : 708–13. [Google Scholar]
  21. Celli J, Duijf P, Hamel BC, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99 : 143–53. [Google Scholar]
  22. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurobiological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 2000; 404 : 99–103. [Google Scholar]
  23. Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289 : 304–6. [Google Scholar]
  24. Meyer G, Perez-Garcia CG, Abraham H, Caput D. Expression of p73 and Reelin in the developing human cortex. J Neurosci 2002; 22 : 4973–86. [Google Scholar]
  25. Allart S, Martin H, Détraves C, et al. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of ΔN-p73. J Biol Chem 2002; 277 : 29063–8. [Google Scholar]
  26. Moll UT, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92 : 4407–11. [Google Scholar]
  27. Wolff A, Technau A, Ihling C, et al. Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 2001; 20 : 1307–17. [Google Scholar]
  28. Naka M, Ozaki T, Takada N, et al. Functional characterization of naturally occurring mutants (P405R and P425L) or p73alpha and p73beta found in neuroblastoma and lung cancer. Oncogene 2001; 14 : 3568–72. [Google Scholar]
  29. Ahomadegbe JC, Tourpin S, Kaghad M, et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancer : prevalence of alterations in inflammatory breast cancers. Oncogene 2000; 19 : 5413–8. [Google Scholar]
  30. Yan H, Yuan W, Velculescu VE, et al. Allelic variation of human gene expression. Science 2002; 297 : 1143. [Google Scholar]
  31. Fillippovich I, Sorokina N, Gatei M, et al. Transactivation deficient p73alpha (p73 Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001; 2 : 514–22. [Google Scholar]
  32. Douc-Rasy S, Barrois M, Echeynne M, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160 : 631–9. [Google Scholar]
  33. Zaika A, Slade N, Erster S, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196 : 765–80. [Google Scholar]
  34. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9 : 229–30. [Google Scholar]
  35. De Laurenzi V, Raschella G, Barcaroli D, et al. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem 2000; 27 : 15226–31. [Google Scholar]
  36. Nikolaev AY, Li M, Puskas N, et al. Parc : a cytoplasmic anchor for p53. Cell 2003; 112 : 29–40. [Google Scholar]
  37. Goldschneider D, Blanc E, Raguenez G, et al. Forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett 2003; 197 : 99–103. [Google Scholar]
  38. Goldschneider D, Blanc E, Raguenez G, et al. Differential response of p53 target to p73 overexpression in SH-SYSY neuroblastoma cell line. J. Cell Sci 2004; 117 : 293–301. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.